Day One Biopharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Day One Biopharmaceuticals's estimated annual revenue is currently $11.5M per year.
- Day One Biopharmaceuticals's estimated revenue per employee is $51,667
- Day One Biopharmaceuticals's total funding is $190M.
- Day One Biopharmaceuticals's current valuation is $872.6M. (January 2022)
Employee Data
- Day One Biopharmaceuticals has 222 Employees.
- Day One Biopharmaceuticals grew their employee count by 48% last year.
Day One Biopharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Day One Biopharmaceuticals?
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
keywords:N/A
$190M
Total Funding
222
Number of Employees
$11.5M
Revenue (est)
48%
Employee Growth %
$872.6M
Valuation
N/A
Accelerator
Day One Biopharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Director, Patient Advocacy | Reveal Email/Phone |
2 | VP Regulatory Science | Reveal Email/Phone |
3 | Senior Manager, Regulatory Science and Operations | Reveal Email/Phone |
4 | VP, Information Technology | Reveal Email/Phone |
5 | VP and Assistant General Counsel | Reveal Email/Phone |
6 | Senior Director RWE / Health Economics | Reveal Email/Phone |
7 | Director, Patient Safety Quality & Compliance | Reveal Email/Phone |
8 | Director, Commercial | Reveal Email/Phone |
9 | Senior Regional Business Director - West at Day One Biopharmaceuticals | Reveal Email/Phone |
10 | Sr. Director Trade & Distribution | Reveal Email/Phone |
Day One Biopharmaceuticals News
Day One Biopharmaceuticals (NASDAQ:DAWN) Lowered to Sell at Zacks Investment Research. Posted by admin on Apr 22nd, 2022.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted...
Wall Street is positive on Day One Biopharmaceuticals Inc (DAWN). On average, analysts give the stock a Strong Buy rating.
SHENZHEN, China, Sept. 1, 2021 /PRNewswire/ -- Dayone Capital announced today the final closing of Dayone Capital Fund I L.P. (" Dayone Fund I"), its first USD-denominated private equity fund, with a total capital commitment exceeding USD630 million, surpassing the initial fundraising target o ...
Dayone Capital Logo Dayone Capital, a Shenzen, China-based private equity firm, closed Dayone Capital Fund I L.P. its first USD-denominated fund, at USD630m. As a debut fund, Dayone Fund I was backed by a group of top global institutional investors, including sovereign funds, fund of funds, fa ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $34.6M | 223 | -4% | $264.5M |
#2 | $43.8M | 226 | 16% | $239.1M |
#3 | $34.2M | 227 | -22% | $35M |
#4 | $55.7M | 230 | 8% | N/A |
#5 | $37.7M | 243 | -7% | N/A |